Psilocybin for Stage IV Cancer
Also known as: Psilocin (active metabolite)
Psilocybin-assisted therapy produces rapid, sustained reduction in end-of-life anxiety and depression in cancer patients.
Mechanism of Action
Psilocybin converts to psilocin, a 5-HT2A receptor agonist that triggers neuroplasticity cascades: BDNF upregulation, dendritic spine growth, default mode network dissolution, and enhanced brain connectivity. In cancer patients, this may facilitate psychological flexibility, meaning-making, and reduction of existential distress.
General mechanism: Tryptamine psychedelic. 5-HT2A agonist. Induces BDNF, neuroplasticity, dendritic spine growth, default mode network dissolution.
Current Evidence
NYU and Johns Hopkins trials show single-dose psilocybin produces rapid, sustained (6+ months) reduction in anxiety and depression in cancer patients. FDA breakthrough therapy designation. 80%+ of participants rated the experience as among the most meaningful of their lives.
Clinical Status: FDA breakthrough therapy designation. Phase III trials for treatment-resistant depression. Oregon and Colorado legal for supervised use.
Safety Profile
Physiologically safe. Psychological risks (anxiety, challenging experiences) require therapeutic setting. Contraindicated in psychosis history. Not addictive.
Key Research Questions
- What is the optimal integration of psilocybin therapy with palliative care for cancer patients?
- Can psilocybin-induced neuroplasticity improve cognitive function in cancer patients on chemotherapy?
- Does psilocybin affect cancer biology through immune modulation (serotonin receptor effects)?